Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 9, 2025
Daily News
September 9, 2025
- JPMA Quality Committee Launches Task Force on DX in Commercial Production
September 9, 2025
- Lilly Japan Ramps Up Seishin Plant with New Building and Packaging Line
September 9, 2025
- Janssen Files TAR-200 in Japan for High-Risk Bladder Cancer
September 9, 2025
- Amicus CEO Confident on US$1 Billion Sales Target as Japan Pompe Launch Gets Underway
September 9, 2025
- GSK Recalls 7 Lots of Omjjara in Japan over Quality Issue
September 9, 2025
- Takeda Nabs Label Expansion for VWD Drug Vonvendi in US
September 9, 2025
- Japan Panel Approves 5 COVID Vaccines for NIP Use from October
September 9, 2025
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…